Since launching my APOE4-dedicated Substack last year, I’ve touched on Rapamycin several times. Why? I remain confident that it’s one of the most promising tools in my AD prevention toolbox.
During an expedition in the 1960’s to the remote, volcanic island in the Pacific Ocean we call Easter Island (locally named Rapa Nui), this complex, organic molecule produced by a bacterium - Streptomyces hygroscopicus - was collected in soil samples. In the early 1970’s researchers isolated a compound from the sample that could stop immune cells and cancer cells from dividing and appropriately named it after its origin. It took another two decades to discover the exact target this molecule, rapamycin, was binding to - and to identify the responsible genes controlling cell growth, division and metabolism in response to nutrients. More detail on the fascinating discovery of Target of Rapamycin (TOR) can be found here.
This post is a deeper dive on the topic, written for physicians, researchers, and scientifically oriented readers, as well as for APOE4 carriers who are considering a rapamycin protocol and are seeking a clear, mechanistic framework to discuss this option with their physician or primary care provider.
In 2021, I had the opportunity to meet the late Dr. Alan Green of Little Neck, New York, who was widely regarded as the pioneer of off-label rapamycin use for Alzheimer disease prevention in APOE4 carriers.
Dr. Green’s practice included more than 700 APOE4 carriers, a group he often described as one of the most neglected patient populations in medicine. He emphasized that among the APOE4 carriers he followed preventively, with the explicit goal of attenuating gene expression and reducing future cognitive risk, he had not observed progression to cognitive impairment in any of his patients during longitudinal follow-up. His full writings on rapamycin, APOE4 and the prevention of AD can be found here.
APOE4 is a lipid- and vascular stress gene
APOE4 is most often discussed in the context of amyloid, cholesterol, or statistical Alzheimer’s risk. Increasingly, however, a different picture has emerged: APOE4 creates an intrinsic vulnerability of the neurovascular unit, long before plaques or cognitive symptoms appear.
One of the clearest mechanistic explanations for this vulnerability centers on blood–brain barrier (BBB) integrity, and specifically, an APOE4-specific inflammatory signaling cascade that does not occur in APOE2 or APOE3 carriers.
The APOE4-specific pathway: Cyclophilin A, MMP-9, and BBB breakdown
As Dr. Green explained to me, in APOE4 carriers - and only in APOE4 carriers - APOE interacts abnormally with vascular pericytes, triggering activation of Cyclophilin A (CypA), a stress-responsive signaling protein.
CypA activation initiates a downstream inflammatory cascade:
ApoE4 activates CypA in pericytes
CypA activates NF-κB and matrix metalloproteinase-9 (MMP-9)
MMP-9 degrades tight junction proteins and basement membrane
Blood–brain barrier integrity is compromised
This BBB breakdown occurs early, often decades before clinical Alzheimer’s disease, and is independent of amyloid-β accumulation.
Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC4047116/
How BBB integrity determines whether APOE4 becomes pathogenic
A crucial implication of the CypA–MMP-9 pathway is that APOE4 pathology appears to be conditional, not inevitable.
When the blood–brain barrier remains intact, APOE4 operates in a relatively protected biochemical environment:
Peripheral ApoB-containing lipoproteins are excluded from the CNS
Oxidized lipids and systemic inflammatory mediators are largely kept out
Astrocytes traffic predominantly endogenous, relatively low-toxicity lipids
Microglia remain in a homeostatic surveillance state
Under these conditions, APOE4’s intrinsic disadvantages (reduced lipid-binding stability, altered receptor interactions) are buffered rather than amplified. This helps explain why many APOE4 carriers remain cognitively normal for decades, and why enhanced Klotho signaling or early-life interventions can markedly attenuate risk.
BBB failure fundamentally changes this equation.
Once the barrier is compromised, the brain is exposed to a qualitatively different lipid environment:
Plasma-derived, often oxidized lipoproteins enter the CNS
Astrocytes shift from lipid export to lipid droplet accumulation
Microglia adopt lipid-laden, pro-inflammatory phenotypes
APOE4 is repeatedly forced into inflammatory clearance roles
This transition converts a manageable lipid trafficking vulnerability into a chronic lipid overload and inflammatory amplification state - the condition under which APOE4 consistently performs worst.
Preserving BBB integrity therefore prevents the upstream event that transforms APOE4 from a fragile transport protein into a pathological amplifier.
Where rapamycin enters the picture
Rapamycin’s relevance in APOE4 is often misunderstood as being primarily related to longevity or generic autophagy enhancement. Dr. Green’s clinical rationale is much more specific.
By inhibiting mTORC1 signaling, rapamycin suppresses activation of Cyclophilin A, reduces MMP-9 activity, and preserves BBB integrity. In doing so, it prevents the entry of inflammatory and oxidized lipid species into the CNS, maintains a low-flux lipid environment, and likely spares APOE4 from repeated inflammatory activation.
In this framework, rapamycin is not treating Alzheimer’s pathology directly. It is preventing the upstream vascular event that precipitates lipid trafficking failure, neuroinflammation, and downstream neurodegeneration in genetically vulnerable brains.
One of the consistent findings in aging brains is that mTOR signaling becomes chronically overactive.
When mTOR stays “on”:
autophagy declines
damaged mitochondria accumulate
abnormal proteins aren’t cleared efficiently
inflammation increases
senescent cells persist
neurons become metabolically stressed
Rapamycin partially reverses many of these changes and why it has become one of the most studied longevity drugs.
Closing perspective
The CypA–MMP-9–BBB pathway provides one of the clearest examples of an APOE4-specific, targetable mechanism that precedes amyloid, tau, and overt neurodegeneration. It also offers a unifying explanation for why lipid trafficking abnormalities, glial lipid accumulation, and inflammatory amplification emerge preferentially in APOE4 carriers.
Whether rapamycin ultimately becomes a mainstream preventive tool remains to be seen. But the biology underlying its use in APOE4 is coherent, mechanistically grounded, and consistent with emerging vascular–lipid models of Alzheimer’s disease risk. On a personal note, I’ve been using rapaymycin (once weekly) since 2021 and will continue do so, indefinitely. I’ve had no side effects and while my neutrophils were often slightly below normal ranges in the first years, they’ve meanwhile normalized completely.
mTOR: Alzheimer’s disease prevention for APOE4 carriers
This post is for scientific discussion and educational purposes only and does not constitute medical advice. Rapamycin is an off-label medication with known risks and should only be used under qualified medical supervision.
AI Disclosure: I use AI to help explain complex medical and scientific concepts, edit my writing, and reduce the time it takes to produce these free articles. That said, AI is only as good as the prompts and context it's given, so my queries are laser-focused, detail oriented and posed through the lens of APOE4. I cross-check important information across three different AI platforms, and verify it against the published literature to insure accuracy. Used well, it's an extraordinary research tool. Used poorly, it can be superficial, verbose, and a waste of time
Really appreciate how precisely you've laid out the CypA MMP-9 cascade here, it's a much sharper mechanistic story than the usual "rapamycin is good for autophagy" framing. One thing worth flagging on the "conditional, not inevitable" point: most of the direct evidence for mTOR inhibition protecting BBB integrity comes from models where the barrier is still intact, true primary prevention. There is newer work in ischemic stroke and vascular cognitive impairment models showing mTOR inhibition can also reduce pericyte constriction and support barrier function after injury has already started, not only before it. If that generalizes to APOE4 biology, it would mean rapamycin isn't only useful for carriers who start early, it could still be doing meaningful work for people whose BBB is already somewhat compromised. Worth tracking for anyone trying to figure out how late is too late to start.
Well done, Karin. Thanks. Note: everolimus might be even better than rapamycin, because of the shorter half-life, but we need more research.